Navigate Safety Concerns With Ranitidine and Other Meds

November 2019

Headlines about a probable carcinogen in some Rx and OTC ranitidine products will raise questions about the safety of generic and brand meds.

The buzz is about N-nitrosodimethylamine (NDMA)...the impurity that first sparked recalls of irbesartan, losartan, and valsartan.

Now FDA is investigating how much NDMA is in ranitidine...whether it poses any risk...and the source. In fact, one lab's analysis used high temps to test ranitidine...and the test itself generated NDMA.

Practical advice for a better career, with unlimited access to CE

Hospital Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Practice Up Your Game When Training New Technicians
Shortages Help Your Pharmacy Conserve Heparin
Pediatrics Don't Think of Pediatric Patients as Little Adults
Antibiotics Avoid Mishaps With Antibiotics That Treat "Anaerobes"
Hypoglycemia Expect to See New Glucagon Products on Home Med Lists
Heart Failure Keep Heart Failure Patients Safe as Their Med Regimens Change
Med Safety Navigate Safety Concerns With Ranitidine and Other Meds
Diabetes Think of Rybelsus as the Tablet Version of Injectable Ozempic
Breast Cancer Reduce Errors With Breast Cancer Prevention Meds
HIV & AIDS Don't Be Surprised to See Descovy Used to Prevent HIV

Navigate Safety Concerns With Ranitidine and Other Meds

Practical advice for a better career, with unlimited access to CE

Table of Contents